Kisqali (ribociclib) — United Healthcare
Recurrent or metastatic endometrial carcinoma
Preferred products
- letrozole
Initial criteria
- Diagnosis of recurrent or metastatic endometrial cancer
- AND Tumor is estrogen receptor (ER)-positive
- AND Used in combination with letrozole
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Kisqali therapy
Approval duration
12 months